Interaction between Bacteria and the Immune System for Cancer Immunotherapy: The α-GalCer Alliance.
alpha-galactosylceramide
biomarkers
colorectal cancer
iNKT
immunotherapy
microbiome
microbiota
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
24 May 2022
24 May 2022
Historique:
received:
06
05
2022
revised:
19
05
2022
accepted:
22
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Non-conventional T cells, such as γδ T and invariant natural killer T (iNKT) cells, are emerging players in fighting cancer. Alpha-galactosylceramide (α-GalCer) is used as an exogenous ligand to activate iNKT cells. Human cells don't have a direct pathway producing α-GalCer, which, however, can be produced by bacteria. We searched the literature for bacteria strains that are able to produce α-GalCer and used available sequencing data to analyze their presence in human tumor tissues and their association with survival. The modulatory effect of antibiotics on the concentration of α-GalCer was analyzed in mice. The human gut bacteria
Identifiants
pubmed: 35682578
pii: ijms23115896
doi: 10.3390/ijms23115896
pmc: PMC9180740
pii:
doi:
Substances chimiques
Galactosylceramides
0
alpha-galactosylceramide
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Immunother Cancer. 2019 Jul 10;7(1):176
pubmed: 31292005
Front Immunol. 2021 Aug 13;12:707734
pubmed: 34484205
Sci Rep. 2021 Apr 14;11(1):8154
pubmed: 33854094
PLoS Biol. 2013 Jul;11(7):e1001610
pubmed: 23874157
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Mol Immunol. 2015 Dec;68(2 Pt A):94-7
pubmed: 26141240
J Immunol. 2012 Apr 15;188(8):3928-39
pubmed: 22412194
Mol Clin Oncol. 2021 May;14(5):93
pubmed: 33767862
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
J Anus Rectum Colon. 2021 Jan 28;5(1):11-24
pubmed: 33537496
Br J Cancer. 2011 Mar 1;104(5):856-62
pubmed: 21285991
Clin Immunol. 2011 Aug;140(2):119-29
pubmed: 21095162
Annu Rev Immunol. 2007;25:297-336
pubmed: 17150027
J Lipid Res. 2017 Jun;58(6):1247-1258
pubmed: 28373486
Sci Rep. 2021 Jan 11;11(1):391
pubmed: 33432015
J Immunother Cancer. 2019 Nov 6;7(1):287
pubmed: 31694714
Cancer Lett. 2015 Jan 28;356(2 Pt B):579-88
pubmed: 25304368
Protein Cell. 2021 May;12(5):426-435
pubmed: 33296049
Gut. 2022 Apr;71(4):734-745
pubmed: 34006584
Cell Host Microbe. 2021 Feb 10;29(2):281-298.e5
pubmed: 33382980
Front Neurol. 2021 Feb 05;12:615593
pubmed: 33613432
Front Immunol. 2020 Aug 20;11:1819
pubmed: 32973759
Science. 2020 May 29;368(6494):973-980
pubmed: 32467386
Front Genet. 2019 Mar 15;10:213
pubmed: 30930939
Oncoimmunology. 2018 Feb 12;7(6):e1428156
pubmed: 29872551
FEBS Lett. 2018 Dec;592(23):3835-3864
pubmed: 29802621
Immunity. 2014 Oct 16;41(4):543-54
pubmed: 25367571
J Exp Clin Cancer Res. 2021 Oct 16;40(1):327
pubmed: 34656142
J Med Chem. 1995 Jun 9;38(12):2176-87
pubmed: 7783149
Immunity. 2018 Mar 20;48(3):453-473
pubmed: 29562195
Front Immunol. 2019 Mar 18;10:533
pubmed: 30936882
PLoS One. 2022 Mar 3;17(3):e0264652
pubmed: 35239725
Nat Commun. 2020 Jul 20;11(1):3644
pubmed: 32686686
Eur J Cancer. 2021 Jul;151:25-34
pubmed: 33962358
Nature. 2021 Apr;592(7852):138-143
pubmed: 33731925
J Lipid Res. 2019 Nov;60(11):1892-1904
pubmed: 31484693
Front Oncol. 2021 Jan 14;10:604531
pubmed: 33520714
J Thorac Oncol. 2019 Aug;14(8):1378-1389
pubmed: 31026576
Clin Cancer Res. 2005 Oct 15;11(20):7322-7
pubmed: 16243803
mSphere. 2018 Nov 14;3(6):
pubmed: 30429227